. Author manuscript; available in PMC: 2015 Jun 1.

Published in final edited form as: Am J Transplant. 2014 Apr 17;14(6):1346–1355. doi: 10.1111/ajt.12698

Table 5.

Efficacy observations: N = 36 (end of study 6 months)

End point	N (%)
Patient survival	36 (100)
Graft survival	36 (100)
Treated BCAR	5 (13.9)
Banff scored
1A (Day 10)	1
1B (Day 16)	1
2A (Days 11, 14 and 20)	3
2B or 3	0
Graft function
Delayed graft function (all), n ¼36	2 (5.6)
Delayed graft function (deceased donors), n = 8	2 (25)
Estimated GFR (cc/min) (Day 180), n¼36	55.6±10
Measured GFR (cc/min/1.73m²) (Day 180), n = 23	65.7 ±26
Urine protein/creatinine
(Day 90)	0.17 ±0.12
(Day 180) n¼27	0.13±0.11
Donor-specific antibody
n = 22 tested; 14 not tested
Day 90	0
Day 180	0

BCAR, biopsy-confirmed acute rejection.